Loading
Life sciences · Journal article
Metabolites · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates significant anti-obesity and hypoglycemic effects in high-fat-diet (HFD)-induced obese models. However, both clinical and preclinical evidence indicates that semaglutide discontinuation inevitably leads to body weight rebound and progressive metabolic deterioration, severely compromising long-term therapeutic efficacy. Methods: To assess whether Lacticaseibacillus paracasei LP-18 alleviates post-semaglutide metabolic deterioration, we first confirmed its anti-obesity effect in HFD-fed mice, then used a three-stage model: HFD-induced obesity (4 weeks), semaglutide treatment (4 weeks), and withdrawal with or without L. paracasei LP-18 (4 weeks). Results:L. paracasei LP-18 supplementation effectively prevented post-discontinuation weight rebound and reduced cumulative energy intake while maintaining glucose homeostasis through decreased fasting and postprandial blood glucose levels. L. paracasei LP-18 also ameliorated dyslipidemia, reduced liver weight and hepatic lipid deposition, and attenuated white adipose tissue expansion and adipocyte hypertrophy. Mechanistically, L. paracasei LP-18 enriched beneficial taxa (Lacticaseibacillus, Bifidobacterium, Faecalibaculum) and depleted obesity-associated genera (Oribacterium, Anaerotruncus, Dorea), while restoring colonic barrier integrity via increased mucus layer thickness, goblet cell density, and upregulation of Muc2, ZO-1, and Occludin. Conclusions: These findings suggest that L. paracasei LP-18 is a promising probiotic strategy to alleviate post-semaglutide weight rebound and metabolic dysfunction, and its beneficial effects are associated with modulation of gut microbiota and preservation of intestinal barrier integrity.